(Q37778312)

23 August 2017

1 reference

title

Perspectives in drug development for metastatic renal cell cancer (English)

1 reference

23 August 2017

Bristi Basu

1

1 reference

PubMed ID

20689997

23 August 2017

Tim Eisen

series ordinal

2

1 reference

23 August 2017

1 June 2010

1 reference

23 August 2017

1 reference

23 August 2017

5

1 reference

23 August 2017

2

1 reference

23 August 2017

139-156

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-010-0149-2

23 August 2017

0 references

cites work

VHL and HIF signalling in renal cell carcinogenesis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11523-010-0149-2

VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation

21 January 2018

1 reference

12 December 2020

Evaluation of HIF-1 inhibitors as anticancer agents

1 reference

12 December 2020

Basic Fibroblast Growth Factor (FGF-2) In Renal Cell Carcinoma, Which is Indistinguishable From that in Normal Kidney, Is Involved in Renal Cell Carcinoma Growth

1 reference

12 December 2020

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

1 reference

12 December 2020

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

12 December 2020

Targeting HIF-1 for cancer therapy

1 reference

12 December 2020

Hypoxia inducible factor-1 independent pathways in tumor angiogenesis.

1 reference

12 December 2020

Loss of PTEN facilitates HIF-1-mediated gene expression

1 reference

12 December 2020

Cancer statistics, 1999.

1 reference

12 December 2020

Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis

1 reference

12 December 2020

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

1 reference

12 December 2020

Impact of anti-angiogenic treatments on metastatic renal cell carcinoma

1 reference

12 December 2020

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

1 reference

12 December 2020

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings

1 reference

12 December 2020

Mechanisms of adverse effects of anti-VEGF therapy for cancer

1 reference

12 December 2020

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

12 December 2020

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

1 reference

12 December 2020

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

1 reference

12 December 2020

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

12 December 2020

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

alphaPlGF: a new kid on the antiangiogenesis block

1 reference

12 December 2020

Recent investigations of histone deacetylase inhibitors in renal cell carcinoma.

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells

1 reference

12 December 2020

Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma

1 reference

12 December 2020

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

12 December 2020

A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

1 reference

12 December 2020

Using protein expressions to predict survival in clear cell renal carcinoma

1 reference

12 December 2020

Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma

1 reference

12 December 2020

Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells.

1 reference

12 December 2020

Heat shock proteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents

1 reference

12 December 2020

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy

1 reference

12 December 2020

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

1 reference

12 December 2020

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

12 December 2020

Loss of tumor suppressor protein PTEN during renal carcinogenesis.

1 reference

12 December 2020

Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.

1 reference

12 December 2020

Targeting tumor angiogenesis with histone deacetylase inhibitors

1 reference

12 December 2020

Histone deacetylase inhibitors: multifunctional anticancer agents.

1 reference

12 December 2020

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

12 December 2020

Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy.

1 reference

12 December 2020

Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique

1 reference

12 December 2020

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

12 December 2020

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

1 reference

12 December 2020

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

12 December 2020

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

12 December 2020

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

12 December 2020

Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy

1 reference

12 December 2020

Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases.

1 reference

12 December 2020

Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma

1 reference

12 December 2020

Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters

1 reference

12 December 2020

Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity

1 reference

12 December 2020

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

1 reference

12 December 2020

Natural products as sources of new drugs over the last 25 years

1 reference

12 December 2020

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

12 December 2020

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

1 reference

12 December 2020

Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney

1 reference

12 December 2020

Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.

1 reference

12 December 2020

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor

1 reference

12 December 2020

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

12 December 2020

An overview of small-molecule inhibitors of VEGFR signaling

1 reference

12 December 2020

The HIF pathway as a therapeutic target

1 reference

12 December 2020

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

1 reference

12 December 2020

VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling.

1 reference

12 December 2020

Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma

1 reference

12 December 2020

Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma

1 reference

12 December 2020

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

12 December 2020

Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney

1 reference

12 December 2020

Adverse effects of anticancer agents that target the VEGF pathway

1 reference

12 December 2020

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

1 reference

12 December 2020

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

12 December 2020

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

12 December 2020

Comparing antibody and small-molecule therapies for cancer

1 reference

12 December 2020

Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles

1 reference

12 December 2020

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

12 December 2020

Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling

1 reference

12 December 2020

The changing natural history of renal cell carcinoma

1 reference

12 December 2020

Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels.

1 reference

12 December 2020

Immunotherapy for advanced renal cell cancer

1 reference

12 December 2020

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

1 reference

12 December 2020

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

1 reference

12 December 2020

Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif

1 reference

12 December 2020

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

12 December 2020

mTOR and cancer: insights into a complex relationship

1 reference

12 December 2020

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Vitespen: a vaccine for renal cancer?

1 reference

12 December 2020

Stratification of risk factors in renal cell carcinoma

1 reference

12 December 2020

The role of molecular markers in the staging of renal cell carcinoma

1 reference

12 December 2020

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

12 December 2020

Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on.

1 reference

12 December 2020

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

12 December 2020

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

1 reference

12 December 2020

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

12 December 2020

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

12 December 2020

Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth

1 reference

12 December 2020

VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma

1 reference

12 December 2020

VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling

1 reference

12 December 2020

The von Hippel-Lindau tumor suppressor protein

1 reference

12 December 2020

Perifosine: update on a novel Akt inhibitor.

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis

1 reference

12 December 2020

Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor.

1 reference

12 December 2020

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

12 December 2020

Protein kinase inhibitors: the tyrosine-specific protein kinases

1 reference

12 December 2020

Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma

1 reference

12 December 2020

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

1 reference

12 December 2020

Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.

1 reference

12 December 2020

p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1.

1 reference

12 December 2020

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

12 December 2020

An assessment of the current use of human interferons in therapy of urological cancers

1 reference

12 December 2020

Angiopoietin and Tie signaling pathways in vascular development

1 reference

12 December 2020

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer

1 reference

12 December 2020

Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.

1 reference

12 December 2020

PI3K/Akt signalling pathway and cancer.

1 reference

12 December 2020

10.1007/S11523-010-0149-2

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20689997